Enteral lactoferrin to prevent infection for very preterm infants: The ELFIN RCT

Health Technology Assessment

Volumn 22, Issue 74, 2018, Pages I-60

  Griffiths, James ^a   Jenkins, Paula ^a   Vargova, Monika ^a   Bowler, Ursula ^a   Juszczak, Edmund ^a   King, Andrew ^a   Linsell, Louise ^a   Murray, David ^a   Partlett, Christopher ^a   Patel, Mehali ^b   Berrington, Janet ^c   Embleton, Nicholas ^c   Dorling, Jon ^d   Heath, Paul T ^e   McGuire, William ^f   Oddie, Sam ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Bliss   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF YORK   (United Kingdom)

^g BRADFORD INSTITUTE FOR HEALTH RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOFERRIN; PLACEBO; SUCROSE;

ALL CAUSE MORTALITY; ARTICLE; CONTROLLED STUDY; COW MILK; ENTERAL DRUG ADMINISTRATION; GENDER; GESTATIONAL AGE; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFANT; INFANT MORTALITY; INFECTION RISK; INTESTINE FLORA; LENGTH OF STAY; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; METABOLITE; MULTIPARA; NECROTIZING ENTEROCOLITIS; NEONATAL INTENSIVE CARE UNIT; NEWBORN; NEWBORN MORBIDITY; PREGNANCY; PREMATURITY; PRIMIPARA; RANDOMIZED CONTROLLED TRIAL; RETROLENTAL FIBROPLASIA; RISK REDUCTION; UNITED KINGDOM; ANIMAL; BOVINE; ENTERIC FEEDING; FEMALE; INFECTION; MALE;

ANIMALS; CATTLE; ENTERAL NUTRITION; ENTEROCOLITIS, NECROTIZING; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, PREMATURE, DISEASES; INFECTION; LACTOFERRIN; MALE;

EID: 85058904090     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta22740     Document Type: Article

References (65)

1. Duley L, Uhm S, Oliver S, Preterm Birth Priority Setting Partnership Steering Group. Top 15 UK research priorities for preterm birth. Lancet 2014; 383:2041–2. https://doi.org/10.1016/S0140-67361460989-2
2. Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011; 96:F9–F14. https://doi.org/10.1136/adc.2009.178798
3. Cailes B, Kortsalioudaki C, Buttery J, Pattnayak S, Greenough A, Matthes J, et al. Epidemiology of UK neonatal infections: the neonIN infection surveillance network. Arch Dis Child Fetal Neonatal Ed 2018; 103:F547–53. https://doi.org/10.1136/archdischild-2017-313203
4. Chapman RL, Faix RG. Persistent bacteremia and outcome in late onset infection among infants in a neonatal intensive care unit. Pediatr Infect Dis J 2003; 22:17–21. https://doi.org/10.1097/01.inf.0000042922.10767.10
5. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis 2006; 19:290–7. https://doi.org/10.1097/01.qco.0000224825.57976.87
6. Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Trial of Indomethacin Prophylaxis in Preterms Investigators. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics 2009; 123:313–18. https://doi.org/10.1542/peds.2008-0377
7. Gordon A, Isaacs D. Late onset neonatal Gram-negative bacillary infection in Australia and New Zealand: 1992–2002. Pediatr Infect Dis J 2006; 25:25–9. https://doi.org/10.1097/01.inf.0000195628.35980.2e
8. Isaacs D, Fraser S, Hogg G, Li HY. Staphylococcus aureus infections in Australasian neonatal nurseries. Arch Dis Child Fetal Neonatal Ed 2004; 89:F331–5. https://doi.org/10.1136/adc.2002.009480
9. Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed 2006; 91:F188–92. https://doi.org/10.1136/adc.2005.082024
10. Isaacs D; Australasian Study Group for Neonatal Infections. A ten year, multi-centre study of coagulase negative staphylococcal infections in Australasian neonatal units. Arch Dis Child Fetal Neonatal Ed 2003; 88:F89–93. https://doi.org/10.1136/fn.88.2.F89
11. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD, National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004; 292:2357–65. https://doi.org/10.1001/jama.292.19.2357
12. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Semin Perinatol 2003; 27:293–301. https://doi.org/10.1016/S0146-00050300046-6
13. Fowlie PW, Schmidt B. Diagnostic tests for bacterial infection from birth to 90 days – a systematic review. Arch Dis Child Fetal Neonatal Ed 1998; 78:F92–8. https://doi.org/10.1136/fn.78.2.F92
14. Malik A, Hui CP, Pennie RA, Kirpalani H. Beyond the complete blood cell count and C-reactive protein: a systematic review of modern diagnostic tests for neonatal sepsis. Arch Pediatr Adolesc Med 2003; 157:511–16. https://doi.org/10.1001/archpedi.157.6.511
15. Buttery JP. Blood cultures in newborns and children: optimising an everyday test. Arch Dis Child Fetal Neonatal Ed 2002; 87:F25–8. https://doi.org/10.1136/fn.87.1.F25
16. Gordon A, Isaacs D. Late-onset infection and the role of antibiotic prescribing policies. Curr Opin Infect Dis 2004; 17:231–6. https://doi.org/10.1097/00001432-200406000-00010
17. Isaacs D. Unnatural selection: reducing antibiotic resistance in neonatal units. Arch Dis Child Fetal Neonatal Ed 2006; 91:F72–4. https://doi.org/10.1136/adc.2005.074963
18. Murphy BP, Armstrong K, Ryan CA, Jenkins JG. Benchmarking care for very low birthweight infants in Ireland and Northern Ireland. Arch Dis Child Fetal Neonatal Ed 2010; 95:F30–5. https://doi.org/10.1136/adc.2009.160002
19. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet 2017; 390:1770–80. https://doi.org/10.1016/S0140-67361731002-4
20. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 2005; 62:2576–87. https://doi.org/10.1007/s00018-005-5372-0
21. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol 2008; 606:163–94. https://doi.org/10.1007/978-0-387-74087-4_6
22. Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010; 1:440–64. https://doi.org/10.4161/viru.1.5.12983
23. Reddy V, Bhaskaram C, Raghuramulu N, Jagadeesan V. Antimicrobial factors in human milk. Acta Paediatr Scand 1977; 66:229–32. https://doi.org/10.1111/j.1651-2227.1977.tb07838.x
24. Legrand D. Overview of lactoferrin as a natural immune modulator. J Pediatr 2016; 173:S10–5. https://doi.org/10.1016/j.jpeds.2016.02.071
25. González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents 2009; 33:301.e1–8. https://doi.org/10.1016/j.ijantimicag.2008.07.020
26. Ochoa TJ, Cleary TG. Effect of lactoferrin on enteric pathogens. Biochimie 2009; 91:30–34. https://doi.org/10.1016/j.biochi.2008.04.006
27. Tian H, Maddox IS, Ferguson LR, Shu Q. Influence of bovine lactoferrin on selected probiotic bacteria and intestinal pathogens. Biometals 2010; 23:593–6. https://doi.org/10.1007/s10534-010-9318-0
28. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des 2009; 15:1956–73. https://doi.org/10.2174/138161209788453202
29. Berlutti F, Schippa S, Morea C, Sarli S, Perfetto B, Donnarumma G, Valenti P. Lactoferrin downregulates pro-inflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive Escherichia coli strains. Biochem Cell Biol 2006; 84:351–7. https://doi.org/10.1139/o06-039
30. Wakabayashi H, Takakura N, Yamauchi K, Tamura Y. Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin Vaccine Immunol 2006; 13:239–45. https://doi.org/10.1128/CVI.13.2.239-245.2006
31. Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I, Polito G, Guarino A. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res 2007; 61:410–14. https://doi.org/10.1203/pdr.0b013e3180332c8d
32. Raghuveer TS, McGuire EM, Martin SM, Wagner BA, Rebouché CJ, Buettner GR, Widness JA. Lactoferrin in the preterm infants’ diet attenuates iron-induced oxidation products. Pediatr Res 2002; 52:964–972. https://doi.org/10.1203/00006450-200212000-00024
33. Magnuson JS, Henry JF, Yip TT, Hutchens TW. Structural homology of human, bovine, and porcine milk lactoferrins: evidence for shared antigenic determinants. Pediatr Res 1990; 28:176–81. https://doi.org/10.1203/00006450-199028020-00019
34. Vorland LH, Ulvatne H, Andersen J, Haukland H, Rekdal O, Svendsen JS, Gutteberg TJ. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis 1998; 30:513–17. https://doi.org/10.1080/00365549850161557
35. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005; 62:2588–98. https://doi.org/10.1007/s00018-005-5373-z
36. Appel MJ, van Veen HA, Vietsch H, Salaheddine M, Nuijens JH, Ziere B, de Loos F. Sub-chronic (13-week) oral toxicity study in rats with recombinant human lactoferrin produced in the milk of transgenic cows. Food Chem Toxicol 2006; 44:964–73. https://doi.org/10.1016/j.fct.2005.11.012
37. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on bovine lactoferrin. EFSA J 2012; 10:2701. https://doi.org/10.2903/j.efsa.2012.2701
38. Lingappan K, Arunachalam A, Pammi M. Lactoferrin and the newborn: current perspectives. Expert Rev Anti Infect Ther 2013; 11:695–707. https://doi.org/10.1586/14787210.2013.811927
39. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009; 302:1421–8. https://doi.org/10.1001/jama.2009.1403
40. Barrington KJ, Assaad MA, Janvier A. The Lacuna Trial: a double-blind randomized controlled pilot trial of lactoferrin supplementation in the very preterm infant. J Perinatol 2016; 36:666–9. https://doi.org/10.1038/jp.2016.24
41. Akin IM, Atasay B, Dogu F, Okulu E, Arsan S, Karatas HD, et al. Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. Am J Perinatol 2014; 31:1111–20. https://doi.org/10.1055/s-0034-1371704
42. Kaur G, Gathwala G. Efficacy of bovine lactoferrin supplementation in preventing late-onset sepsis in low birth weight neonates: a randomized placebo-controlled clinical trial. J Trop Pediatr 2015; 61:370–6. https://doi.org/10.1093/tropej/fmv044
43. Ochoa TJ, Zegarra J, Cam L, Llanos R, Pezo A, Cruz K, et al. Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g. Pediatr Infect Dis J 2015; 34:571–6. https://doi.org/10.1097/INF.0000000000000593
44. Sherman MP, Adamkin DH, Niklas V, Radmacher P, Sherman J, Wertheimer F, Petrak K. Randomized controlled trial of talactoferrin oral solution in preterm infants. J Pediatr 2016; 175:68–73.e3. https://doi.org/10.1016/j.jpeds.2016.04.084
45. The ELFIN Trial Investigators Group. Summary protocol for a multi-centre randomised controlled trial of enteral lactoferrin supplementation in newborn very preterm infants (ELFIN). Neonatology 2018; 114:142–8. https://doi.org/10.1159/000488927
46. Abbott J, Berrington J, Bowler U, Boyle E, Dorling J, Embleton N, et al. The speed of increasing milk feeds: a randomised controlled trial. BMC Pediatr 2017; 17:39. https://doi.org/10.1186/s12887-017-0794-z
47. Allmark P, Spedding M. Clinical trials in neonates: ethical issues. Semin Fetal Neonatal Med 2007; 12:318–23. https://doi.org/10.1016/j.siny.2007.01.023
48. Modi N, Doré CJ, Saraswatula A, Richards M, Bamford KB, Coello R, Holmes A. A case definition for national and international neonatal bloodstream infection surveillance. Arch Dis Child Fetal Neonatal Ed 2009; 94:F8–12. https://doi.org/10.1136/adc.2007.126458
49. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33:179–201. https://doi.org/10.1016/S0031-39551634975-6
50. ICROP. An International Classification of Retinopathy of Prematurity. Pediatrics 1984; 74:127–33.
51. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116:1353–60. https://doi.org/10.1542/peds.2005-0249
52. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008; 19:640–8. https://doi.org/10.1097/EDE.0b013e31818131e7
53. DAMOCLES Study Group, NHS Health Technology Assessment Programme. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 2005; 365:711–22. https://doi.org/10.1016/S0140-67360570939-9
54. Guyatt GH, Briel M, Glasziou P, Bassler D, Montori VM. Problems of stopping trials early. BMJ 2012; 344:e3863. https://doi.org/10.1136/bmj.e3863
55. Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP. Lactoferrin: Antimicrobial activity and therapeutic potential. Semin Fetal Neonatal Med 2013; 18:143–9. https://doi.org/10.1016/j.siny.2013.02.001
56. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2012; 129:116–23. https://doi.org/10.1542/peds.2011-0279
57. Oeser C, Vergnano S, Naidoo R, Anthony M, Chang J, Chow P, et al. Neonatal invasive fungal infection in England 2004-2010. Clin Microbiol Infect 2014; 20:936–41. https://doi.org/10.1111/1469-0691.12578
58. Embleton ND, Berrington JE, Dorling J, Ewer AK, Juszczak E, Kirby JA, et al. Mechanisms affecting the gut of preterm infants in enteral feeding trials. Front Nutr 2017; 4:14. https://doi.org/10.3389/fnut.2017.00014
59. Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, et al. A randomized symbiotic trial to prevent sepsis among infants in rural India. Nature 2017; 548:407–12. https://doi.org/10.1038/nature23480
60. Oeser C, Lutsar I, Metsvaht T, Turner MA, Heath PT, Sharland M. Clinical trials in neonatal sepsis. J Antimicrob Chemother 2013; 68:2733–45. https://doi.org/10.1093/jac/dkt297
61. Tamim MM, Alesseh H, Aziz H. Analysis of the efficacy of urine culture as part of sepsis evaluation in the premature infant. Pediatr Infect Dis J 2003; 22:805–8. https://doi.org/10.1097/01.inf.0000083822.31857.43
62. Martin A, Ghadge A, Manzoni P, Lui K, Brown R, Tarnow-Mordi W, LIFT Collaborative Study Group. Protocol for the Lactoferrin Infant Feeding Trial (LIFT): a randomised trial of adding lactoferrin to the feeds of very-low birthweight babies prior to hospital discharge. BMJ Open 2018; 8:e023044. https://doi.org/10.1136/bmjopen-2018-023044
63. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ 2006; 15:677–87. https://doi.org/10.1002/hec.1093
64. Battersby C, Santhalingam T, Costeloe K, Modi N. Incidence of neonatal necrotising enterocolitis in high-income countries: a systematic review. Arch Dis Child Fetal Neonatal Ed 2018; 103:F182–9. https://doi.org/10.1136/archdischild-2017-313880
65. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2015; 2: 7. https://doi.org/10.1002/14651858.CD007137.pub4